Sitemap > Breaking Research > Infectious Diseases
Displaying 1101 - 1150 of 4290 results
- Synthesis, antiviral activity, and pharmacokinetic evaluation of P3 pyridylmethyl analogs of oximinoarylsulfonyl HIV-1 protease inhibitors.
- The immunostimulant RU41740 from Klebsiella pneumoniae activates human cells in whole blood to potentially stimulate innate and adaptive immune responses.
- Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses.
- Intensified and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine.
- Hepatitis B virus genotypes and response to antiviral therapy.
- Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology.
- Assessment of sexual dysfunction in patients with benign prostatic hyperplasia.
- Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma.
- Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention.
- Selective irreversible inhibition of fructose 1,6-bisphosphate aldolase from Trypanosoma brucei.
- Novel HIV-1 integrase inhibitors derived from quinolone antibiotics.
- Identification of novel parasitic cysteine protease inhibitors by use of virtual screening. 2. The available chemical directory.
- Dynamic pharmacophore model optimization: identification of novel HIV-1 integrase inhibitors.
- 2-(2-Thienyl)-5,6-dihydroxy-4-carboxypyrimidines as inhibitors of the hepatitis C virus NS5B polymerase: discovery, SAR, modeling, and mutagenesis.
- Synthesis and antibacterial activity of novel C12 vinyl ketolides.
- Lipolanthionine peptides act as inhibitors of TLR2-mediated IL-8 secretion. Synthesis and structure-activity relationships.
- Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor.
- Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
- A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1.
- Adenoviral gene transfer of a mutant surfactant enzyme ameliorates pseudomonas-induced lung injury.
- Pyranocoumarin, a novel anti-TB pharmacophore: synthesis and biological evaluation against Mycobacterium tuberculosis.
- Sildenafil in the treatment of antipsychotic-induced erectile dysfunction: a randomized, double-blind, placebo-controlled, flexible-dose, two-way crossover trial.
- Modifying toll-like receptor 9 signaling for therapeutic use.
- On the horizon: promising investigational antiretroviral agents.
- Current progress in the development of HIV vaccines.
- Thiol proteases: inhibitors and potential therapeutic targets.
- Antiviral properties of two trimeric recombinant gp41 proteins.
- Entecavir: a new treatment option for chronic hepatitis B.
- Single dose and multiple dose studies of itraconazole nanoparticles.
- Aziridine-2,3-dicarboxylate inhibitors targeting the major cysteine protease of Trypanosoma brucei as lead trypanocidal agents.
- F0F1-ATPase as biosensor to detect single virus.
- The cannabinoid CB1 receptor antagonist SR 141716A induces penile erection by increasing extra-cellular glutamic acid in the paraventricular nucleus of male rats.
- Pharmaceutical and immunological evaluation of a single-dose hepatitis B vaccine using PLGA microspheres.
- Effect of an ATP-sensitive potassium channel opener in subjects with overactive bladder: a randomized, double-blind, placebo-controlled study (ZD0947IL/0004).
- A fast and robust 19F NMR-based method for finding new HIV-1 protease inhibitors.
- Synthesis and SAR studies of diarylpyrrole anticoccidial agents.
- Treatment with anti-TNF monoclonal antibody (c5N) reduces the extent of induced endometriosis in the baboon.
- The NS5A protein of the hepatitis C virus genotype 1a is cleaved by caspases to produce C-terminal-truncated forms of the protein that reside mainly in the cytosol.
- Cutting Edge: The direct action of type I IFN on CD4 T cells is critical for sustaining clonal expansion in response to a viral but not a bacterial infection.
- Epitope enhancement of a CD4 HIV epitope toward the development of the next generation HIV vaccine.
- Voltage-dependent Ca2+-channel block by openers of intermediate and small conductance Ca2+-activated K+ channels in urinary bladder smooth muscle cells.
- Anti-infective monoclonal antibodies: perils and promise of development.
- Recombinant human erythropoietin prevents the death of mice during cerebral malaria.
- Re-formulation of selected DNA vaccine candidates and their evaluation as protein vaccines using a guinea pig aerosol infection model of tuberculosis.
- Prediction of renal allograft rejection by urinary protein analysis using ProteinChip Arrays (surface-enhanced laser desorption/ionization time-of-flight mass spectrometry).
- Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection.
- Adding selectivity to antimicrobial peptides: rational design of a multidomain peptide against Pseudomonas spp.
- Preclinical evaluation of synthetic -2 RANTES as a candidate vaginal microbicide to target CCR5.
- In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis.
- Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels.
< Previous 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 Next >